en · de · es · fr · pt
sermorelin-notes.peptides9002.com › News › Melanocortin Receptor Pharmacology — Quick Reference

Melanocortin Receptor Pharmacology — Quick Reference

By Editorial Desk · published 2026-01-21 · last reviewed 2026-02-19 · News

A practical reference on Bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.

Melanocortin Receptor Pharmacology

The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.

Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.

Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.

Chemical Identity of Bremelanotide

The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

Pt-141 at a glance

PropertyValueNotes
Primary receptor targetMC4RHighest reported agonist potency within the family
Secondary receptor activityMC1R and MC3RLower potency than at MC4R
Elimination half-lifeAbout 2 to 3 hoursMeasured after subcutaneous administration
Plasma protein bindingApproximately 44 percentSpecies- and assay-dependent
Route of administrationSubcutaneous injectionReviewed product uses a single-use device

Bremelanotide Naming and Background

Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.

Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.

Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.

Related pages on this site

Receptor Pharmacology And Signalling

The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.

Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.

Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.

Supporting material

== Synthesis and degradation == Increasing cyclin D1 levels during the G1 phase is induced by mitogenic growth factors primarily through Ras-mediated pathways, and hormones. These Ras-mediated pathways lead to the increase in transcription of cyclin D1, and inhibit its proteolysis and export from the nucleus. Cyclin D1 is degraded by the proteasome upon phosphorylation of threonine 286 and subsequent ubiquitylation via the CRL4-AMBRA1 E3 ubiquitin ligase complex.

Their KOR agonism may be involved in ibogaine's putative antiaddictive effects in the setting of opioid dependence. Analogues with strongly enhanced KOR agonist potency such as oxa-noribogaine, GM-3009, and 4-allyl-6-oxa-noribogainalog have been developed. GM-3009 is under development by Gilgamesh Pharmaceuticals for the treatment of opioid-related disorders. The selective KOR agonist and benzomorphan MR-2034 ((–)-MR-2033) led to the initial discovery in the 1980s that KOR agonists produce hallucinogenic and dysphoric effects as opposed to these effects being mediated by concomitant sigma receptor agonism.

Several of the food issues from the Mercury missions were addressed for the later Gemini missions (1965–1966). Tubes (often heavier than the foods they contained) were abandoned, gelatin coatings were added to the bite-sized cubes to help prevent them from crumbling, and simpler rehydration methods were developed. The menus were also expanded to include items such as shrimp cocktail, chicken and vegetables, toast squares, butterscotch pudding, and apple juice. The crew of Gemini 3 snuck a corned beef sandwich on their spaceflight. Mission Commander Gus Grissom loved corned beef sandwiches, so Pilot John Young brought one along, having been encouraged by fellow astronaut Walter Schirra. However, Young was supposed to eat only approved food, and Grissom was not supposed to eat anything at all. Floating crumbs from the bread posed a potential problem, causing Grissom to put the sandwich away and the astronauts were mildly rebuked by NASA for the act. A congressional hearing was called, forcing NASA deputy administrator George Mueller to promise no repeats, and NASA employed renewed vigilance regarding what astronauts brought along on future missions.

=== Reactions with metals === Even diluted sulfuric acid reacts with many metals via a single displacement reaction, like other typical acids, producing hydrogen gas and salts (the metal sulfate). It attacks reactive metals (metals at positions above copper in the reactivity series) such as iron, aluminium, zinc, manganese, magnesium, and nickel.

Sources: en.wikipedia.org

Notes from published material

=== Carbon dioxide === Humans are the main indoor source of carbon dioxide (CO2) in most occupied buildings. Indoor CO2 concentrations can be used as an indicator of the adequacy of outdoor air ventilation relative to occupancy and metabolic activity. Exposure to elevated indoor CO2 concentrations has been investigated in relation to human health and cognitive performance. Some studies have reported physiological and psychomotor effects at relatively low concentrations, although the evidence is not consistent and it can be difficult to distinguish the effects of CO2 itself from those of other pollutants and human bioeffluents associated with inadequate ventilation. Reviews of the available evidence have reported possible effects on cognitive performance at concentrations above 1000 ppm, particularly during complex tasks, although the evidence remains subject to uncertainty. At concentrations below 5000 ppm, the health effects attributable specifically to CO2 are difficult to distinguish from those associated with other indoor pollutants and inadequate ventilation. Indoor CO2 concentrations are widely used as an indicator of ventilation performance in buildings. Because indoor concentrations are influenced by occupancy, ventilation rates, building characteristics and outdoor conditions, measurements of CO2 can provide information on the adequacy of air exchange in occupied spaces.

==== Quest for milk substitutes ==== Poorer consumers reliant on local infant formula, which was approximately half the price of imported brands, had been left without alternatives to feed their children. Many had lost faith in local brands, with others unsure of which brands were safe. Supermarket shelves had been swept bare from product recalls. Shops in Hong Kong reported a rush for imported formula from cross-border shoppers, with some retailers reportedly rationing their stocks. Some mainlanders were also reportedly rushing to import infant formula from Kinmen. Wet nurses enjoyed a resurgence in popularity in major cities. Some media reports have documented that Chinese sailors and expatriates have been buying local dairy produce in Australia to send back to relatives in China. It had been estimated in 2018 that up to 80% to 90% of infant formula purchased in Australia was destined for China. Following widespread complaints and appeals by exasperated Australian parents unable to find formula for their children, Coles supermarkets resorted to locking baby formula tins away behind the Service Counter, like tobacco products, in order to regulate their sale. The two major supermarkets, Coles and Woolworths, placed a two item limit on baby formula purchases to curb the growing practice of bulk purchasing by predominantly Chinese customers known as daigou, or "personal shoppers".

== Pathophysiology == The thyroid gland is responsible for regulating whole-body metabolism through the production of two major hormones: thyroxine (T4) and triiodothyronine (T3). Of the metabolically active thyroid hormones, 93% is T4 and 7% is T3. T3 is four times more potent than T4 and most T4 is converted to T3 in the tissues. Iodine is necessary for adequate hormone production. Thyroid-stimulating hormone (TSH) is a circulating or serum hormone from the pituitary gland that stimulates the thyroid gland to produce T3 and T4. Hypothyroidism occurs when the thyroid gland does not produce enough T3 and T4. The most common cause of hypothyroidism worldwide is too little dietary iodine. Hashimoto's thyroiditis is the most common cause of hypothyroidism in countries with sufficient dietary iodine. With the cessation of the production of thyroid hormone, the thyroid gland contains enough reserve T3 and T4 to last 2 to 3 months. The thyroid hormones T3 and T4 influence the production by virtually all cells in the body of hundreds of new intracellular proteins and enzymes. This influence includes the expression of the calcium ATPase, regulation of ion channels, oxidative phosphorylation, increased Na-K-ATPase activity, increased carbohydrate metabolism, increased free fatty acids, increased vitamin requirements, and increased overall metabolism.

Sources: en.wikipedia.org

Frequently asked questions

Which receptors does bremelanotide activate?

Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.

Does the compound reach the brain?

Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.

What is known about its half-life?

Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.

What class of compound is PT-141?

It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.

Network